Shares of Dr. Martens plc (LON:DOCS – Get Free Report) fell 9.6% on Friday . The stock traded as low as GBX 72.30 and last traded at GBX 73.80. 4,733,644 shares were traded during mid-day trading, an increase of 115% from the average session volume of 2,203,986 shares. The stock had previously closed at GBX 81.60.
Analysts Set New Price Targets
Separately, Peel Hunt reissued a “buy” rating on shares of Dr. Martens in a report on Thursday. One analyst has rated the stock with a Buy rating and two have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Dr. Martens currently has a consensus rating of “Hold” and an average target price of GBX 6,000.
Check Out Our Latest Report on Dr. Martens
Dr. Martens Trading Down 1.6%
Dr. Martens (LON:DOCS – Get Free Report) last released its quarterly earnings data on Thursday, November 20th. The company reported GBX (0.90) earnings per share for the quarter. Dr. Martens had a return on equity of 18.91% and a net margin of 7.89%. On average, analysts predict that Dr. Martens plc will post 2.5809394 EPS for the current year.
Insider Buying and Selling
In related news, insider Giles Wilson sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, September 1st. The stock was sold at an average price of GBX 91, for a total value of £27,300. Also, insider Ije Nwokori sold 298,675 shares of the stock in a transaction on Wednesday, October 15th. The stock was sold at an average price of GBX 90, for a total transaction of £268,807.50. In the last quarter, insiders acquired 136,960 shares of company stock valued at $12,460,163 and sold 434,460 shares valued at $39,131,400. 2.80% of the stock is owned by corporate insiders.
About Dr. Martens
Founded in 1960, Dr. Martens is an iconic British brand with a global presence. “Docs” or “DMs” were originally
produced for their durability for workers, before being adopted by diverse youth subcultures and associated musical
movements. Today, Dr. Martens has transcended its roots while still celebrating its proud history.
Read More
- Five stocks we like better than Dr. Martens
- Using the MarketBeat Dividend Yield Calculator
- Datavault AI Just Raised Guidance by 400%—Are You Paying Attention?
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Peter Thiel Dumps NVIDIA and Slashes Tesla Stake—Is the AI Bubble About to Pop?
- Consumer Discretionary Stocks Explained
- Why Lithium Americas Could Be a 2030 Power Play—Not a 2025 One
Receive News & Ratings for Dr. Martens Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr. Martens and related companies with MarketBeat.com's FREE daily email newsletter.
